The role of akt activation in the response to chemotherapy in pancreatic cancer

Anticancer Research

Volumn 30, Issue 9, 2010, Pages 3279-3289

  Parsons, Colin M ^a   Muilenburg, Diego ^a   Bowles, Tawnya L ^a   Virudachalam, Subbulakshmi ^a   Bold, Richard J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Akt; Apoptosis; Pancreatic cancer

Indexed keywords

CARBOPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; GEMCITABINE; GLYCOGEN SYNTHASE KINASE; PACLITAXEL; PHOSPHOPROTEIN; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1A;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CONCENTRATION RESPONSE; DOWN REGULATION; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; UPREGULATION; CELL SEPARATION; DRUG EFFECTS; DRUG RESISTANCE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; PANCREAS TUMOR; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SEPARATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 77958578733     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Datta SR, Brunet A and Greenberg ME: Cellular survival: a play in three Akts. Genes Dev 13(22): 2905-2927, 1999.
2. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J and Waterfield MD: Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 17: 615-675, 2001.
3. Luo J, Manning BD and Cantley LC: Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4(4): 257-262, 2003. (Pubitemid 37329790)
4. West KA, Castillo SS and Dennis PA: Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 5(6): 234-248, 2002.
5. Nicholson KM and Anderson NG: The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14(5): 381-395, 2002.
6. Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase Akt pathway in human cancer. Nat Rev Cancer 2(7): 489-501, 2002.
7. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, Shelley SA, Jove R, Tsichlis PN, Nicosia SV and Cheng JQ: Akt1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic trans-formation in NIH3T3 cells. Am J Pathol 159(2): 431-437, 2001.
8. Romashkova JA and Makarov SS: NF-kappaB is a target of Akt in anti-apoptotic PDGF signalling. Nature 401(6748): 86-90, 1999.
9. Zhou BP, Hu MC, Miller SA, Yu Z, Xia W, Lin SY and Hung MC: HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 275(11): 8027-8031, 2000.
10. Fahy BN, Schlieman MG, Virudachalam S and Bold RJ: Inhibition of Akt abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer. J Am Coll Surg 198(4): 591-599, 2004.
11. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S and Reed JC: Regulation of cell death protease caspase-9 by phosphorylation. Science 282(5392): 1318-1321, 1998.
12. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y and Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91(2): 231-241, 1997.
13. Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 3(3): 245-252, 2001.
14. Schlieman MG, Fahy BN, Ramsamooj R, Beckett L and Bold RJ: Incidence, mechanism and prognostic value of activated Akt in pancreas cancer. Br J Cancer 89(11): 2110-2115, 2003. (Pubitemid 38030911)
15. Yamamoto S, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K, Umeshita K, Sakon M, Ishikawa O, Ohigashi H, Nakamori S, Monden M and Aozasa K: Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res 10(8): 2846-50, 2004.
16. Chadha KS, Khoury T, Yu J, Black JD, Gibbs JF, Kuvshinoff BW, Tan D, Brattain MG and Javle MM: Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol 13(7): 933-939, 2006.
17. Ng SSW, Tsao MS, Chow S and Hedley DW: Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 60(19): 5451-5455, 2000.
18. Luo Y, Smith RA, Guan R, Liu X, Klinghofer V, Shen J, Hutchins C, Richardson P, Holzman T, Rosenberg SH and Giranda VL: Pseudosubstrate peptides inhibit Akt and induce cell growth inhibition. Biochemistry 43(5): 1254-1263, 2004.
19. Perugini RA, McDade TP, Jr., Vittimberga FJ and Callery MP: Pancreatic cancer cell proliferation is phosphatidylinositol 3-Kinase dependent. J Surg Res 90: 39-44, 2004.
20. Shah SA, Potter MW, Hedeshian MH, Kim RD, Chart RS and Callery MP: PI-3′ kinase and NF-kappaB cross-signaling in human pancreatic cancer cells. J Gastrointest Surg 5: 603-12, 2001.
21. Arlt A, Gehrz A, Muerkoster S, Vorndamm J, Kruse ML, Folsch UR and Schafer H: Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 22(21): 3243-3251, 2003.
22. Takeda A, Osaki M, Adachi K, Honjo S and Ito H: Role of the phosphatidylinositol 3′-kinase-Akt signal pathway in the proliferation of human pancreatic ductal carcinoma cell lines. Pancreas 28(3): 353-358, 2004.
23. Ng SS, Tsao MS, Nicklee T and Hedley DW: Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res 7(10): 3269-3275, 2001.
24. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB and McConkey DJ: Inhibition of the phosphatidylinositol 3′-kinase-Akt pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 1(12): 989-997, 2002.
25. Su Z, Lebedeva IV, Gopalkrishnan RV, Goldstein NI, Stein CA, Reed JC, Dent P and Fisher PB: A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells. Proc Natl Acad Sci USA 98(18): 10332-10337, 2001.
26. Fahy BN, Schlieman M, Virudachalam S and Bold RJ: Akt inhibition is associated with chemosensitization in the pancreatic cancer cell line MIA-PaCa-2. Br J Cancer 89(2): 391-397, 2003.
27. Fornier M, Risio M, Van Poznak C and Seidman A: HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology 16(10): 1340-1348, 2002.
28. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F and Slamon D: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18(13): 2241-2251, 1999.
29. Pan X, Arumugam T, Yamamoto T, Levin PA, Ramachandran V, Ji B, Lopez-Berestein G, Vivas-Mejia PE, Sood AK, McConkey DJ and Logsdon CD: Nuclear factor-kappaB p65/re1A silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin Cancer Res 14(24): 8143-8151, 2008.
30. Clark AS, West K, Streicher S and Dennis PA: Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1(9): 707-717, 2002.
31. Page C, Lin HJ, Jin Y, Castle VP, Nunez G, Huang M and Lin J: Overexpression of Akt/Akt can modulate chemotherapy-induced apoptosis. Anticancer Res 20(1A): 407-416, 2000. (Pubitemid 30189787)
32. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL and Reddy SA: The PI3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 23(53): 8571-8580, 2004.
33. Wendel HG, Malina A, Zhao Z, Zender L, Kogan SC, Cordon-Cardo C, Pelletier J and Lowe SW: Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res 66(15): 7639-7646, 2006.
34. Ihle NT, Lemos R Jr, Wipf P, Yacoub A, Mitchell C, Siwak D, Mills GB, Dent P, Kirkpatrick DL and Powis G: Mutations in the phosphatidylinositol-3- kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 69(1): 143-150, 2009.
35. Buck E, Eyzaguirre A, Haley JD, Gibson NW, Cagnoni P and Iwata KK: Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. Mol Cancer Ther 5(8): 2051-2059, 2006.
36. Tzeng CW, Frolov A, Frolova N, Jhala NC, Howard JH, Vickers SM, Buchsbaum DJ, Heslin MJ and Arnoletti JP: EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients. J Surg Res 143(1): 20-26, 2007.
37. Mitsuuchi Y, Johnson SW, Selvakumaran M, Williams SJ, Hamilton TC and Testa JR: The phosphatidylinositol 3-kinase/Akt signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res 60(19): 5390-5394, 2000.
38. Héliez C, Baricault L, Barboule N and Valette A: Paclitaxel increases p21 synthesis and accumulation of its Akt-phosphorylated form in the cytoplasm of cancer cells. Oncogene 22(21): 3260-3268, 2003. (Pubitemid 36712938)